Last reviewed · How we verify
PF-07104091 monotherapy dose escalation (pf-07104091-monotherapy-dose-escalation)
PF-07104091 monotherapy dose escalation (generic name: pf-07104091-monotherapy-dose-escalation) is a drug developed by Pfizer Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | pf-07104091-monotherapy-dose-escalation |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07104091 monotherapy dose escalation CI brief — competitive landscape report
- PF-07104091 monotherapy dose escalation updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about PF-07104091 monotherapy dose escalation
What is PF-07104091 monotherapy dose escalation?
PF-07104091 monotherapy dose escalation (pf-07104091-monotherapy-dose-escalation) is a pharmaceutical drug developed by Pfizer Inc..
Who makes PF-07104091 monotherapy dose escalation?
PF-07104091 monotherapy dose escalation is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of PF-07104091 monotherapy dose escalation?
pf-07104091-monotherapy-dose-escalation is the generic (nonproprietary) name of PF-07104091 monotherapy dose escalation.
What development phase is PF-07104091 monotherapy dose escalation in?
PF-07104091 monotherapy dose escalation is in Phase 2.